KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Deferred Tax Assets (2016 - 2019)

Biocryst Pharmaceuticals filings provide 10 years of Current Deferred Tax Assets readings, the most recent being $9000.0 for Q1 2019.

  • On a quarterly basis, Current Deferred Tax Assets fell 94.08% to $9000.0 in Q1 2019 year-over-year; TTM through Mar 2019 was $9000.0, a 94.08% decrease, with the full-year FY2018 number at $9000.0, down 95.71% from a year prior.
  • Current Deferred Tax Assets hit $9000.0 in Q1 2019 for Biocryst Pharmaceuticals, roughly flat from $9000.0 in the prior quarter.
  • In the past five years, Current Deferred Tax Assets ranged from a high of $218000.0 in Q3 2017 to a low of $8000.0 in Q3 2018.
  • Median Current Deferred Tax Assets over the past 5 years was $88000.0 (2015), compared with a mean of $88000.0.
  • Biggest five-year swings in Current Deferred Tax Assets: soared 147.06% in 2017 and later plummeted 96.33% in 2018.
  • Biocryst Pharmaceuticals' Current Deferred Tax Assets stood at $90000.0 in 2015, then fell by 5.56% to $85000.0 in 2016, then soared by 147.06% to $210000.0 in 2017, then crashed by 95.71% to $9000.0 in 2018, then changed by 0.0% to $9000.0 in 2019.
  • The last three reported values for Current Deferred Tax Assets were $9000.0 (Q1 2019), $9000.0 (Q4 2018), and $8000.0 (Q3 2018) per Business Quant data.